^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PBI-200

    i
    Other names: PBI-200
    Associations

    News

    Trials
    Company:
    Biohaven
    Drug class:
    TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor
    Related drugs:
    Associations

    News

    Trials
    1m
    Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors (clinicaltrials.gov)
    P1, N=29, Terminated, Pyramid Biosciences | Phase classification: P1/2 --> P1
    Phase classification • Metastases
    |
    WT1 (WT1 Transcription Factor) • EWSR1 (EWS RNA Binding Protein 1) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    WT1 expression • NTRK positive • NTRK fusion • WT1 positive
    |
    PBI-200
    2ms
    Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors (clinicaltrials.gov)
    P1/2, N=29, Terminated, Pyramid Biosciences | N=74 --> 29 | Trial completion date: Jun 2024 --> Jul 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2024 --> Jul 2023; Sponsor terminated development of PBI-200
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    WT1 (WT1 Transcription Factor) • EWSR1 (EWS RNA Binding Protein 1) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    WT1 expression • NTRK positive • NTRK fusion • WT1 positive
    |
    PBI-200
    5ms
    Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors (clinicaltrials.gov)
    P1/2, N=74, Active, not recruiting, Pyramid Biosciences | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    WT1 (WT1 Transcription Factor) • EWSR1 (EWS RNA Binding Protein 1) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    WT1 expression • NTRK positive • NTRK fusion • WT1 positive
    |
    PBI-200
    2years
    Pyramid Biosciences and Caris Life Sciences Announce MI Trials Collaboration for Clinical Trial Matching in Support of Study for Patients with NTRK Fusion Solid Tumors (PRNewswire)
    "Pyramid Biosciences, Inc., and Caris Life Sciences® (Caris), today announced a collaboration to enhance identification of potential patients with NTRK fusion-driven cancers for participation in the ongoing Phase 1/2 trial (PBI-200-101) of Pyramid's lead oncology program PBI-200, a best-in-class, next-generation, highly CNS-penetrant TRK inhibitor...Caris' tailored MI Trials offering helps match the right patients to the right biopharma trials based on both the individual patient's molecular tumor profile and the eligibility requirements of a given study."
    Trial status • Licensing / partnership
    |
    PBI-200
    over2years
    PBI-200: in vivo efficacy of a novel, highly CNS-penetrant next generation TRK inhibitor (SNO 2021)
    A BaF3 xenograft model encoding the LMNA-NTRK1 gene fusion and G595R solvent front mutation showed superior efficacy with PBI-200 relative to first-generation compounds larotrectinib and entrectinib, and equivalent efficacy to the second-generation compound selitrectinib, in terms of tumor growth inhibition. Together, these data suggest that PBI-200 has potential as a best-in-class, highly CNS-penetrant next generation TRKi. A Phase 1/2 clinical trial evaluating PBI-200 in NTRK fusion-positive patients, including patients with PBT, is ongoing (NCT04901806).
    Preclinical
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • LMNA (Lamin A/C) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK1 fusion • LMNA-NTRK1 fusion • NTRK positive • NTRK1 G595R • NTRK fusion
    |
    Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • selitrectinib (BAY 2731954) • PBI-200
    almost3years
    Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors (clinicaltrials.gov)
    P1/2, N=74, Recruiting, Pyramid Biosciences | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    WT1 (WT1 Transcription Factor) • EWSR1 (EWS RNA Binding Protein 1) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    WT1 expression • NTRK positive • NTRK fusion • WT1 positive
    |
    PBI-200
    almost3years
    Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors (clinicaltrials.gov)
    P1/2, N=74, Not yet recruiting, Pyramid Biosciences
    Clinical • New P1/2 trial
    |
    WT1 (WT1 Transcription Factor) • EWSR1 (EWS RNA Binding Protein 1) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    WT1 expression • NTRK positive • NTRK fusion • WT1 positive
    |
    PBI-200